{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:06:00Z","timestamp":1782954360992,"version":"3.54.5"},"reference-count":52,"publisher":"Informa UK Limited","issue":"13","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2023,11,10]]},"DOI":"10.1080\/10428194.2023.2254430","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:58:03Z","timestamp":1694721483000},"page":"2071-2080","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias"],"prefix":"10.1080","volume":"64","author":[{"given":"Ainhoa","family":"Gomez-Lumbreras","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mercadal Vilchez","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, UT, USA"},{"name":"Cellular Therapy and Regenerative Medicine, University of Utah, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Villa-Zapata","sequence":"additional","affiliation":[{"name":"Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Couriel","sequence":"additional","affiliation":[{"name":"Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, UT, USA"},{"name":"Cellular Therapy and Regenerative Medicine, University of Utah, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"National Cancer Institute. NIH. CAR T cells: engineering patients\u2019 immune cells to treat their cancers. Available from: https:\/\/www.cancer.gov\/about-cance HYPERLINK \"https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells\"r\/treatment\/research\/car-t-cells. 2022."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2022.2033057"},{"key":"e_1_3_5_5_1","unstructured":"U.S. Food & Drug Administration. Approved cellular and gene therapy products. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"e_1_3_5_6_1","unstructured":"U.S. Food & Drug Administration L information. KYMRIAH\u00ae (tisagenlecleucel) suspension for intravenous infusion. Available from: https:\/\/www.fda.gov\/media\/107296\/download."},{"key":"e_1_3_5_7_1","unstructured":"U.S. Food & Drug Administration L information. YESCARTA\u00ae (axicabtagene ciloleucel) suspension for intravenous infusion. Available from: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20 HYPERLINK \"https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-YESCARTA.pdf\"& HYPERLINK \"https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-YESCARTA.pdf\"%20biologics\/published\/Package-Insert-YESCARTA.pdf."},{"key":"e_1_3_5_8_1","unstructured":"U.S. Food & Drug Administration L information. BREYANZI\u00ae (lisocabtagene maraleucel) suspension for intravenous infusion. Available from: https:\/\/www.fda.gov\/media\/145711\/download."},{"key":"e_1_3_5_9_1","unstructured":"U.S. Food & Drug Administration L. TECARTUS\u00ae (brexucabtagene autoleucel) suspension for intravenous infusion. Available from: https:\/\/www.fda.gov\/media\/140409\/download."},{"key":"e_1_3_5_10_1","unstructured":"U.S. Food & Drug Administration L information. ABECMA\u00ae (idecabtagene vicleucel) suspension for intravenous infusion. Available from: https:\/\/www.fda.gov\/media\/147055\/down HYPERLINK \"https:\/\/www.fda.gov\/media\/147055\/download\"load."},{"key":"e_1_3_5_11_1","unstructured":"U.S. Food & Drug Administration L information. CARVYKTITM(ciltacabtagene autoleucel) suspension for intravenous infusion. Available from: https:\/\/www.fda.gov\/media\/1 HYPERLINK \"https:\/\/www.fda.gov\/media\/156560\/download\"56560\/download."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.104058"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001972"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.026"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.702644"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2021.05.003"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061501"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.03.009"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S321202"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.21037\/sci-2021-008"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.11.003"},{"key":"e_1_3_5_33_1","unstructured":"U.S. Food & Drug Administration. Cellular & Gene Therapy Products. [cited 2022 Sep 10]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products. 2022."},{"key":"e_1_3_5_34_1","unstructured":"FDA Adverse Events Reporting System (FAERS). [cited 2021 Feb 1]. Available from: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest HYPERLINK \"https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files\"-quarterly-data-files."},{"key":"e_1_3_5_35_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). MedDRA\u00ae the Medical Dictionary for Regulatory Activities. Available from: https:\/\/www.meddra.org\/."},{"key":"e_1_3_5_36_1","unstructured":"FDA. DA Adverse Event Reporting System (FAERS) Public Dashboard. [cited 2021 Sep 21] Available from: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"key":"e_1_3_5_37_1","unstructured":"MedDRA. Introductory guide. Available from: https:\/\/www.meddra. org\/sites\/default\/files\/guidance\/file\/smq_intguide_19_0_english.pdf. 2016)."},{"key":"e_1_3_5_38_1","unstructured":"MedDRA\u00ae. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 20.1 September 2017 Accessible at https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/smq_intguide_20_1_english.pdf"},{"key":"e_1_3_5_39_1","unstructured":"Screening for adverse reactions in EudraVigilance. Europe: European Medicines Agency. December 19th 2016. Accessible at https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0351-3"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00642"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0115-x"},{"key":"e_1_3_5_44_1","unstructured":"Weber J. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. Adv Inflamm Res."},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0150-2"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.003"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004475"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03106-z"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01194-z"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.08.036"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20140307"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2023.2254430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T11:45:22Z","timestamp":1736163922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2023.2254430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":52,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,11,10]]}},"alternative-id":["10.1080\/10428194.2023.2254430"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2023.2254430","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}